Investment analysts at StockNews.com began coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Rating) in a report issued on Friday. The firm set a "sell" rating on the biotechnology company's stock.
Genocea Biosciences Price Performance
Shares of Genocea Biosciences stock opened at $0.00 on Friday. The company has a fifty day moving average price of $0.01 and a 200 day moving average price of $0.01. The company has a current ratio of 1.35, a quick ratio of 1.35 and a debt-to-equity ratio of 0.24. Genocea Biosciences has a twelve month low of $0.00 and a twelve month high of $1.48. The stock has a market cap of $35,240.40, a price-to-earnings ratio of 0.00 and a beta of 1.61.
Get Genocea Biosciences alerts:Genocea Biosciences Company Profile
(Get Rating)
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.Featured Articles
- Get a free copy of the StockNews.com research report on Genocea Biosciences (GNCA)
- Your Decision to Buy Palantir May Simply Be a Matter of Time
- Are Caterpillar and Deere Setting Up to Rally in 2023?
- Mullen Automotive Gets a Jolt as the I-GO Arrives in Europe
- Will The Sun Shine On These 3 Large-Cap Solar Stocks In 2023?
- Lucid Motors Faces a Reality That May Cloud a Bullish Perception
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
